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Nitrofurantoin has well-described associations with a range of adverse pulmonary effects. We report the
case of a 72-year old woman with relapsing pneumonitis secondary to the intermittent use of nitro-
furantoin, a pattern of disease not well-represented in the literature. The case is also noteworthy as the
diagnosis was initially overlooked due to the circumstances of the patient’s medication use. Lung biopsy
was avoided by detailed history taking.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case report
A 72-year old never smoker presented with lethargy and exer-
tional breathlessness of two months’ duration. Nine months previ-
ously on a holiday to Italy she had experienced malaise and minor
haemoptysis, the latter of which recurred intermittently. The only
past medical history was of osteoporosis, for which she took calcium
supplements. Initial history taking revealed no other regular medi-
cation use or exposure to birds, animals or organic materials.
A chest radiograph two months prior to initial hospital assess-
ment showed consolidation in the right mid zone and prominent
markings in both lower zones (Fig. 1); these changes were resolving
one month later (Fig. 2). Initial spirometry produced a forced expi-
ratory volume in1 s (FEV1) 2.03L and forced vital capacity (FVC) 2.43L
(113 and 111% predicted). Carbon monoxide transfer factor (TLCO)
was 62% predicted. Blood tests including C-reactive protein (CRP), full
blood count and erythrocyte sedimentation rate (ESR) were normal.
Computed tomography (CT) shortly after her initial visit
revealed widespread parenchymal distortion in the mid and lower
zones and ground glass change towards the apices but no mass
lesion or lymphadenopathy (Fig. 3). Bronchoalveolar lavage
revealed no evidence of bacterial, mycobacterial or viral infection,
and cytology showed non-speciﬁc inﬂammation.
One month after initial outpatient assessment, the patient’s
symptoms had greatly improved. However, two days after re-
attending clinic she was admitted to hospital with acute bilateral.
. Turner), chris.barber2@sth.
-NC-ND license.pleuritic pain and marked dyspnoea. Clinical examination was
unremarkable other than a heart rate of 106 but a chest radiograph
showed further right mid zone consolidation (Fig. 4). Her CRP was
33 mg/L and neutrophil count 9.6  109/L. She tested negatively for
human immunodeﬁciency virus and an autoimmune screen was
negative. No cause for this exacerbation was identiﬁed but her
symptoms improved rapidly following empirical treatment with
oral prednisolone for a presumed diagnosis of non-speciﬁc inter-
stitial pneumonia. Early outpatient follow up was organised with
consideration of lung biopsy.
The cause of this patient’s relapsing respiratory condition only
became apparent at the next clinic visit, following a very detailed
enquiry into the course of events between her previous clinic
attendance and the acute hospital admission. At this time the
patient volunteered she had taken nitrofurantoin several hours
prior to becoming unwell, in order to prevent post-coital cystitis.
On further questioning, she had been taking this medication
intermittently over the preceding 18-month period.
Avoiding nitrofurantoin completely led to a good symptomatic
recovery over the followingmonths, and no further exacerbations. High
resolutionCT fourweeks after hospital admission showed improvement
from the previous study (Fig. 5) and TLCO three months post-discharge
was also signiﬁcantly better at 91% predicted.
2. Discussion
Although occurring in less than 1% of patients taking the
drug, nitrofurantoin is well-recognised to have adverse pulmo-
nary effects including acute interstitial pneumonia, organising
pneumonia, pulmonary ﬁbrosis, acute respiratory distress
syndrome, diffuse alveolar haemorrhage, pleural effusion and
Fig. 1. Chest radiograph two months prior to ﬁrst hospital clinic visit.
Fig. 2. Chest radiograph one month prior to ﬁrst hospital clinic visit.
Fig. 3. CT image shortly after ﬁrst hospital clinic visit.
Fig. 4. Chest radiograph at time of acute hospital admission.
Fig. 5. CT four weeks after avoidance of nitrofurantoin.
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nitrofurantoin-induced lung disease, 94% of individuals were
women (median age of 72) prescribed the drug daily to prevent
recurrent urinary tract infections.2 Following cessation of
nitrofurantoin use, and the use of steroids in some cases, clinical
outcome is usually favourable, although residual radiological
abnormalities can persist.2e4
This case was unusual due to the relapsing pattern of illness. To
our knowledge it is the ﬁrst report of lung disease caused by
intermittent rather than chronic daily usage of nitrofurantoin. The
diagnosis here was initially missed because the patient did not
report taking nitrofurantoin when asked about medication. The
case highlights the importance of detailed history taking in
complex cases, and that patient modesty or embarrassment
may lead to important omissions of personally sensitive key
information.
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